Rate My Professor Yukihiro Ono

Ohno's research in pharmacology centers on neuropharmacology, investigating dopamine and serotonin systems, glial functions, and Kir4.1 channels in astrocytes related to epilepsy, Parkinson's disease, schizophrenia, depression, and anxiety disorders. Notable publications include "Emerging Roles of Astrocyte Kir4.1 Channels in the Pathogenesis and Treatment of Brain Diseases" (International Journal of Molecular Sciences, 2021), "Mechanisms Underlying Dopaminergic Regulation of Nicotine-Induced Kinetic Tremor" (Frontiers in Pharmacology, 2022), "Imbalance of glutamatergic and GABAergic neurotransmission in audiogenic seizure-susceptible Leucine-rich glioma-inactivated 1 (Lgi1)-mutant rats" (Heliyon, 2023), and "Ameliorative effects of Kir4.1 channel inhibitors on lipopolysaccharide-induced cognitive impairment via BDNF/TrkB signaling pathway" (Journal of Pharmacological Sciences, 2025). He has authored books such as "Serotonin: The mediator that spans evolution" (Elsevier, 2019) and "図解 薬害副作用学 改訂3版" (南山堂, 2023). Ohno is a Fellow of the Collegium Internationale Neuro-Psychopharmacologicum since 2011 and holds editorial positions including Associate Editor of Biological Pharmaceutical Bulletin, Section Editor of Journal of Pharmacological Sciences, and board member for International Journal of Molecular Sciences and CNS & Neurological Disorders-Drug Targets. He has contributed to committees of the Japanese Pharmacological Society, Japanese Society of Neuropsychopharmacology, Japanese Epilepsy Society, and Japanese Society of Toxicology, and delivered lectures on epilepsy pathogenesis and astrocyte modulation at conferences such as the Japanese Epilepsy Society annual meetings.